Irinotecan liposomal - CSPC Ouyi Pharmaceutical
Alternative Names: Irinotecan liposome injection - CSPC Ouyi PharmaceuticalLatest Information Update: 28 Aug 2024
At a glance
- Originator CSPC Ouyi Pharmaceutical
- Developer CSPC Ouyi Pharmaceutical; CSPC Pharmaceutical Group
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma; Biliary cancer; Small cell lung cancer; Squamous cell cancer
- Clinical Phase Unknown Pancreatic cancer
- No development reported Breast cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral, Injection)
- 27 Aug 2024 CSPC Ouyi Pharmaceutical plans a phase III trial for Adenocarcinoma (IV, Infusion) (NCT06571461)
- 26 Aug 2024 Shanghai Runshi Pharmaceutical Technology plans phase-I/II trial for Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in August 2024 (Unspecified route) , (NCT06577376)